Infosys Q1 Earnings Match Estimates, Revenues Increase Y/Y

Infosys (INFY) reported Q1 fiscal 2026 earnings of $0.19 per share, aligning with estimates, while revenues surged 4.8% year-over-year to $4.94 billion, exceeding consensus by 2.1%, primarily driven by strong growth in Manufacturing, Financial Services, and Energy & Utilities segments. Despite a 3.4% increase in operating income, the operating margin slightly contracted 30 basis points to 20.8%. The company also issued fiscal 2026 guidance, forecasting constant currency revenue growth of 1-3% and an operating margin range of 20-22%.

Analysis

Infosys reported mixed results for its first quarter of fiscal 2026, characterized by a top-line beat offset by tepid forward guidance. The company's revenue grew 4.8% year-over-year to $4.94 billion, surpassing consensus estimates by 2.1%, while earnings of $0.19 per share were in line with expectations. Growth was primarily fueled by strong performance in Europe, which saw a 12.3% constant currency increase, and in the Manufacturing (+14.72%) and Financial Services (+6.23%) segments. However, this was counterbalanced by near-stagnant growth in the critical North American market (+0.4% cc) and a notable decline in the Life Sciences segment (-6.41%). While operating income rose 3.4% YoY, profitability remains a key concern as the operating margin contracted by 30 basis points to 20.8%. The most significant takeaway is the company's cautious outlook, forecasting full-year fiscal 2026 revenue growth of only 1-3% in constant currency, which implies a material deceleration from the Q1 growth rate. The guided operating margin of 20-22% suggests profitability will likely remain constrained, with the Q1 result already at the low end of this range.

Key Decisions for Investors

• Investors should temper growth expectations for the fiscal year, as the full-year revenue guidance of 1-3% indicates a significant slowdown from the 4.8% growth reported in Q1.
• Closely monitor operating margins in subsequent quarters, as the Q1 margin of 20.8% is at the bottom of the company's full-year guidance range of 20-22%, signaling potential for further pressure.
• Scrutinize future earnings reports for a turnaround in the sluggish North American market and the declining Life Sciences segment, as over-reliance on European and Manufacturing growth presents a concentration risk.
• Given the soft guidance, maintaining a neutral or 'Hold' position appears prudent until there are clearer catalysts for growth re-acceleration or margin expansion.